Grufity logo
Grufity logo
ROIV

ROIV - Roivant Sciences Ltd. Stock Price, Fair Value and News

$39.73-1.29 (-3.14%)
Delayed as of 15 Sep 2026, 11:25 am ET

ROIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ROIV Price Action

Last 7 days

17.4%

Last 30 days

13.3%

Last 90 days

34.9%

Trailing 12 Months

191.3%

ROIV RSI Chart

ROIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ROIV Valuation

Market Cap

29.6B

Price/Earnings (Trailing)

-110.85

Price/Sales (Trailing)

3.9K

EV/EBITDA

-98.81

Price/Free Cashflow

-36.08

ROIV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ROIV Fundamentals

ROIV Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-33.55%

Rev. Growth (Qtr)

-42.78%

ROIV Earnings

Earnings (TTM)

-267.2M

Earnings Growth (Yr)

30.69%

Earnings Growth (Qtr)

-153.55%

ROIV Profitability

EBT Margin

-3848.65%

Return on Equity

-5.43%

Return on Assets

-5.04%

Free Cashflow Yield

-2.77%

ROIV Investor Care

Shares Dilution (1Y)

5.88%

Diluted EPS (TTM)

-0.47

ROIV Alerts

  • 3 major insider sales recently.
Revenue & Growth

How Roivant Sciences Ltd. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20268.3M7.5M--
202529.1M23.2M20.3M13.3M
202449.9M36.2M37.0M30.5M
202331.5M36.1M40.7M45.3M
202255.3M51.9M50.4M43.1M
202123.8M30.0M42.6M61.2M
202067.7M56.7M45.7M34.8M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Roivant Sciences Ltd.

ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
 CEO
 WEBSITEhttps://roivant.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES904

Roivant Sciences Ltd. Frequently Asked Questions

ROIV is the stock ticker symbol of Roivant Sciences Ltd.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Roivant Sciences Ltd. is 29.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, ROIV's PE ratio (Price to Earnings) is -110.85 and Price to Sales (PS) ratio is 3.93 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ROIV PE ratio will change depending on the future growth rate expectations of investors.